Genomics - Research and Markets - RSS Feed

MicroRNA Research Trends 2009 Market Report

press@researchandmarkets.com — Tue, 18 Aug 2009 14:32:15 GMT

This is the latest and most up-to-date market analysis report addressing microRNA research market trends The focus of this report is to document the technical and commercial trends operative in the microRNA research space with emphasis upon the analysis of microRNAs and microRNA associations with...

Biopharmaceutical Expression Systems and Genetic Engineering Technology

press@researchandmarkets.com — Tue, 14 Jul 2009 11:11:26 GMT

New expression systems and recent improvements available for current systems have the potential to revolutionize the biopharmaceutical industry!Lower costs and efficiencies of newer expression systems are driving these changes This book provides you with the information you need to make the shift to...

Oomycete Genetics and Genomics: Diversity, Interactions and Research Tools

press@researchandmarkets.com — Thu, 02 Jul 2009 14:17:34 GMT

This book brings together the knowledge from and tools for genetic and genomic research into oomycetes to help solve the problems this pathogen poses to crops and animals Armed with the information presented here, researchers can use oomycete data to solve practical problems and gain insight into...

U.S. DNA-Based Diagnostic and Test Market

press@researchandmarkets.com — Thu, 14 May 2009 11:11:17 GMT

Market Trends, New Product Trends, Technology Trends, Distribution Structure and 10 Notable Companies DNA-based testing is moving into a new phase Transformational technologies are allowing complex genetic (specific gene) and genomic (large numbers of genes) tests to move from research-only labs...

Automation in Proteomics and Genomics: An Engineering Case-Based Approach

press@researchandmarkets.com — Wed, 13 May 2009 15:08:03 GMT

In the last decade DNA sequencing costs have decreased over a magnitude, largely because of increasing throughput by incremental advances in tools, technologies and process improvements Further cost reductions in this and in related proteomics technologies are expected as a result of the development...

Next-Generation Genome Sequencing : Towards Personalized Medicine

press@researchandmarkets.com — Mon, 02 Feb 2009 11:50:38 GMT

Written by leading experts from industry and academia, this comprehensive resource addresses recent developments in next generation DNA sequencing technology and their impact on genome research, drug discovery and health care As such, it presents a detailed comparative analysis of commercially...

Plant Proteomics

press@researchandmarkets.com — Fri, 30 Jan 2009 16:00:52 GMT

Confidently face the challenges of proteomics research specific to plant science with the information in Plant Proteomics, which will introduce you to the techniques and methodologies required for the study of representative plant species Read about proteomics studies in Arabidopsis, rice, and...

Genomics in Drug Discovery and Development

press@researchandmarkets.com — Thu, 29 Jan 2009 17:58:30 GMT

Early characterization of toxicity and efficacy would significantly impact the overall productivity of pharmaceutical R&D and reduce drug candidate attrition and failure By describing the available platforms and weighing their relative advantages and disadvantages, including microarray data...

Competitor Analysis: CD20 Antibodies

press@researchandmarkets.com — Wed, 28 Jan 2009 15:07:43 GMT

The present Competitive Intelligence Report about anti-CD20 antibodies used to treat B-cell mediated malignancies and rheumatoid arthritis provides a competitor evaluation in the field of R&D projects with anti-CD20 antibodies as of January 2009 The chimeric anti-CD20 antibody rituximab (Rituxan &...

The RNA Purification Market: Evaluating Competitive Dynamics & Establishing Benchmarks

press@researchandmarkets.com — Mon, 26 Jan 2009 12:55:06 GMT

RNA purification is a critical first step for preparing biological samples for a multitude of analytical techniques including real-time quantitative PCR, reverse transcription PCR, microarrays, Northern blot analysis, nuclease protection assays, RNA mapping, in vitro translation and cDNA library...

The Market for SNP Genotyping Products & Services

press@researchandmarkets.com — Mon, 26 Jan 2009 12:33:57 GMT

A single nucleotide polymorphism (SNP), a single base pair variation, is the most commonly occurring variation in DNA SNPs provide a powerful approach to understanding the connection between genetic variation and its physical manifestation, and as such, are a main focus of the pharmacogenomics arena...

The Septins

press@researchandmarkets.com — Wed, 07 Jan 2009 12:42:48 GMT

Septins have recently attracted a strong interest form researchers of diverse fields of biological and medical sciences A comprehensive publication on septin biology was much needed, and this book is the first of its kind Featuring contributions from key investigators in this area of research, this...

The Survey of Gene Modified (GM) Crops in China

press@researchandmarkets.com — Thu, 04 Dec 2008 11:48:22 GMT

Genetically modified (GM) crops are one of the major fields of glyphosate use in the world In 2008, Chinese government approved the commercial production of four kinds of GM crops, which shows that Chinese government will open its door wider to GM crops from now on These years, China 's GM industry...

Gene Transfer: Delivery and Expression of DNA and RNA, A Laboratory Manual

press@researchandmarkets.com — Tue, 28 Oct 2008 17:22:49 GMT

Understanding gene function and regulation requires rigorous testing in live cells and organisms Recent advances have provided a variety of new strategies for delivering DNA and RNA into cells and probing their expression, as well as new clinical applications that rely upon the introduction of...

Genetic Variation: A Laboratory Manual

press@researchandmarkets.com — Tue, 28 Oct 2008 17:17:04 GMT

Genetic Variation: A Laboratory Manual is the first compendium of protocols specifically geared towards genetic variation studies, and includes thorough discussions on their applications for human and model organism studies Intended for graduate students and professional scientists in clinical and...

Ethical Issues in Governing Biobanks

press@researchandmarkets.com — Tue, 21 Oct 2008 08:34:53 GMT

Population genomics research drawing on genetic databases has expanded rapidly, with some of this information being combined in 'biobanks' Managing this information in an appropriate way is a highly complex ethical issue in the health policy arena This book combines theoretical and empirical...

Next Generation Sequencing for Life Science R&D: Advancing to the $1,000 Genome

press@researchandmarkets.com — Wed, 06 Aug 2008 14:02:47 GMT

This report examines the emerging, fast-growing worldwide market for next-generation genome sequencing systems and services The makers of the new sequencing systems are competing in the race to drive down the cost of sequencing a human genome to $1,000 or less At that cost, life scientists will be...

Next Generation Sequencing for Life Science R&D: Advancing to the $1,000 Genome.

press@researchandmarkets.com — Fri, 18 Jul 2008 14:52:22 GMT

Telecommunication Equipment Technology Report - 2008

press@researchandmarkets.com — Tue, 08 Jul 2008 09:17:40 GMT

Telecom carriers continue to shift their capital expenditure to next-generation infrastructure and technologies that offer the proposition of revenue growth or of lowering operating expenses. Further, capex in emerging markets is increasing over three times as fast as in developing regions.

Secondly, wireless infrastructure equipment remains a hot growth area, with increase in mobile penetration expected in emerging markets. In addition, service providers are expected to invest in WiMax infrastructure as the current 3G and 3.5G is too slow for mobile broadband applications and 4G is still a few years away.

The report forecasts the market size of telecommunication equipment over the period 2007-2010. Further, the total market is segmented into various geographic regions and verticals. The report also presents markets size for major countries in various regions. In addition, the report identifies major selling drivers for the telecommunication equipment for the major verticals.

This report can help IT vendors identify target geographies and verticals. Furthermore, the identified sales drivers can be used to penetrate these accounts or increase current share of the customers wallet.

TechNavio Insights is a set of reports based on TechNavio - a market intelligence platform for the IT industry. It builds on the intelligence available within TechNavio, and leverages on the custom research experience of the Technology Navigators. TechNavio is built on years of experience of the authors in deep dive custom research and consulting for over 30 Fortune 500 companies and numerous large and mid-sized companies.

Plant Biotechnology and Genetics: Principles, Techniques and Applications

press@researchandmarkets.com — Wed, 02 Jul 2008 11:48:37 GMT

This report explores contemporary techniques and applications of plant biotechnology, illustrating the tremendous potential this technology has to change our world by improving the food supply As an introductory text, its focus is on basic science and processes It guides students from plant biology...

Genomics World Markets 2008

press@researchandmarkets.com — Wed, 21 May 2008 15:25:17 GMT

Genomics is transforming the pharmaceutical industry Companies are moving from drug discovery and development based on medicinal chemistry to the design of drugs based on information provided by genomics Virtually all of the major pharmaceutical houses have either formed partnerships with genomics...

Next-Generation Genomic Sequencing: Market Evaluation

press@researchandmarkets.com — Thu, 10 Apr 2008 15:13:50 GMT

A Panel Discussion Among Genomic Sequencing Experts Study Description and Objectives To assess potential future uptake of the Illumina 1G Genome Analyzer (using Solexa sequencing technology) and the competitive environment developing in the ‘next-generation sequencing’ space From current...

How to Get Ahead with Pharmacogenomics

press@researchandmarkets.com — Mon, 07 Apr 2008 15:36:20 GMT

Introduction Pharmacogenomics (PGx) is an evolutionary—not a revolutionary—process The “blockbuster” business model is, of course, still relevant to the pharmaceutical industry, but at the same time, companies must adopt technologies that will enable them to develop better drugs—value-added drugs...

Concepts in Genetic Medicine

press@researchandmarkets.com — Thu, 14 Feb 2008 17:22:34 GMT

Concepts in Genetic Medicine offers a coherent collection of uniformly organized short reviews in the field of therapeutic genetic medicine Each chapter focuses on a current topic ("concept") to elucidate issues in development of genetic treatments for discuses, presenting critical challenges,...

Chemical and Functional Genomic Approaches to Stem Cell Biology and Regenerative Medicine

press@researchandmarkets.com — Wed, 13 Feb 2008 16:25:10 GMT

Functional genomic approaches including genome-wide expression analysis, large-scale gain and loss of function genetic studies with cDNA and RNAi libraries, chemical genomics, high throughput cell-based screens, and proteomics are just emerging to rapidly fill the gap in our knowledge of stem cell...

Environmental Microbiology: From Genomes to Biogeochemistry

press@researchandmarkets.com — Tue, 12 Feb 2008 15:18:26 GMT

This well-referenced, inquiry-driven text presents an up-to-date and comprehensive understanding of the emerging field of environmental microbiology -Coherent and comprehensive treatment of the dynamic, emerging field of environmental microbiology -Emphasis on real-world habitats and selective...

Testicular Chromosome Structure and Gene Expression

press@researchandmarkets.com — Tue, 12 Feb 2008 14:28:52 GMT

The 2005 Workshop, published as volume 1061 of the Annals, focused on testicular cell dynamics and brought an influx of new information into the field of male reproduction Several laboratories have been actively investigating the endocrine signals between the germ and somatic cells of the testis,...

Understanding Genomics and Global Health Impacts

press@researchandmarkets.com — Mon, 11 Feb 2008 14:23:54 GMT

With the exclusion of viruses, which are intracellular parasites, living beings are split up into two universal categories First, there are eukaryotes whose cells have an intricate compartmental internal construction; they comprise algae, fungi, plants and animals Second, there are prokaryotes,...

Transforming Drug Discovery through Genomics and Proteomics

press@researchandmarkets.com — Mon, 11 Feb 2008 14:17:29 GMT

In medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are discovered and/or designed In the past most drugs have been discovered either by identifying the active ingredient from traditional remedies or by serendipitous discovery A new approach has been to...

Hepatotoxicity: From Genomics to In Vitro and In Vivo Models

press@researchandmarkets.com — Fri, 01 Feb 2008 14:27:34 GMT

This book addresses all the current, up-to-date developments in this scientific discipline Liver is the chief metabolizing site in the body, and thus, it is a major target organ for drug and chemical toxicity Therefore, hepatotoxicity is an important endpoint in the safety evaluation of drugs and...

Oxford Transcription Factor: A Practical Approach

press@researchandmarkets.com — Thu, 31 Jan 2008 16:47:01 GMT

Transcription factors are proteins that interact with specific DNA sequences to enable transcription to occur. The popular first edition was published five years ago and all chapters have been extensively revised and four new chapters added to give a comprehensive guide to all the methods required to analyse transcription factors.

Since the publication of the first edition five years ago, a wide range of new methodologies have been developed to facilitate studies on both isolated parts of the genome and the genome as a whole. This new edition has been updated and expanded so that it provides a comprehensive guide to the methods currently available to characterize the function and activity of an individual transcription factor. All the original chapters have been fully updated or rewritten and additional chapters cover the use of in vitro transcription assays, analysis of chromatin structure, and use of the genomic binding site assay and analysis of transcription factor modifications. As with the previous edition, the book starts with a series of chapters concerned with characterizing the proteins binding to a specific DNA sequence and then a chapter on more detailed characterization of the protein itself. The next two chapters describe the isolation of cDNA clones encoding a transcription factor using oligonucleotides predicted from protein sequence and screening of a cDNA expression library. Chapter 6 deals with identification of transcription factors based on sequence homology analysis by both experimental screening and database searches. Chapter 7 is a new chapter that describes methods of identifying the target genes of a previously uncharacterized factor. The next chapters deal with analysis of transcription factor function. Chapter 8 deals with general techniques, and then the following chapters cover the specialized techniques of in vitro transcription assays using transcriptionally active nuclear extracts derived from rat brain, and analysis of the effect

Dictionary of DNA and Genome Technology

press@researchandmarkets.com — Fri, 25 Jan 2008 16:42:30 GMT

DNA technology has a vital role in diverse fields such as criminal investigation and gene therapy - dynamic areas involving many specialized terms and techniques This unique dictionary offers current, detailed, accessible information to lecturers, researchers, students and technicians throughout the...

Cortical Development: Genes and Genetic Abnormalities

press@researchandmarkets.com — Thu, 17 Jan 2008 15:23:41 GMT

To understand the brain and its devastating diseases, we need to reveal the mechanisms that produce it and the ways in which it can constantly change throughout a lifetime This book features a timely and insightful discussion between developmental neurobiologists and clinicians who deal with...

Seattle Genetics, Inc:Premium Company Profile

press@researchandmarkets.com — Tue, 08 Jan 2008 16:32:30 GMT

Introduction

Seattle Genetics is a clinical development stage biopharmaceutical company mainly focused on researching and developing monoclonal antibody-based therapies utilizing its proprietary monoclonal antibody-drug conjugates (ADC) technology for the treatment of wide range of cancer and autoimmune diseases.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

Seattle Geneticss product focus is on the development of monoclonal antibody-based therapies for the treatment of patients with cancer and autoimmune diseases. It intends to advance its product pipeline through its strong internal expertisec Seattle Genetics derives all of its revenues from collaboration and licensing agreements. During the period 2002-2006, the companys total revenues increased at a CAGR of 56% from $2 million to $10 million. This represents an absolute total growth of +$8 million for the total revenues during the same period. The company revenues are expected to increase at a CAGR of 53%, from $10 million in 2006 to $55 million in 2010. This represents an absolute growth of +$45 million for the same period. License, collaboration and other revenues will be the major contributor to the total revenue growth out to 2010.

Reasons to Purchase

Access all the important information and analysis on the company in a single report Understand companys strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to companys adjusted five year financial data along with key ratios and market capitalization

U.S. DNA-Based Diagnostic and Test Market

press@researchandmarkets.com — Mon, 07 Jan 2008 16:31:51 GMT

CuraGen Corporation - SWOT Framework Analysis

press@researchandmarkets.com — Thu, 03 Jan 2008 17:06:53 GMT

SWOT Analysis, is a strategic planning tool used to evaluate the Strengths, Weaknesses, Opportunities, and Threats involved in a project or in a business venture. It involves specifying the objective of the business venture or project and identifying the internal and external factors that are favorable and unfavorable to achieving that objective.

The aim of any SWOT analysis is to identify the key internal and external factors that are important to achieving the objective. SWOT analysis groups key pieces of information into two main categories:

Internal factors - The strengths and weaknesses internal to the organization.
External factors - The opportunities and threats presented by the external environment.

The internal factors may be viewed as strengths or weaknesses depending upon their impact on the organization's objectives. What may represent strengths with respect to one objective may be weaknesses for another objective. The factors may include all of the 4P's; as well as personnel, finance, manufacturing capabilities, and so on. The external factors may include macroeconomic matters, technological change, legislation, and socio-cultural changes, as well as changes in the marketplace or competitive position. The results are often presented in the form of a matrix.

SWOT analysis is just one method of categorization and has its own weaknesses. For example, it may tend to persuade companies to compile lists rather than think about what is really important in achieving objectives. It also presents the resulting lists uncritically and without clear prioritization so that, for example, weak opportunities may appear to balance strong threats.

Stem Cells 2007-2008 Market Report

press@researchandmarkets.com — Tue, 18 Dec 2007 16:32:02 GMT

This is the latest Stem Cells Market Report This report presents an up-to-date thorough analysis of the stem cells landscape including quantitative market analysis, industry metrics, intellectual property landscape as well as all the major industry events over the past 18 months The report contains...

Emerging Generic Drug Markets in Europe

press@researchandmarkets.com — Tue, 18 Dec 2007 12:37:10 GMT

A comparative study of high growth markets of opportunity Emerging Generic Drug Markets in Europe: France, Italy, Portugal, Spain The many generic companies and investors looking to Asian and Latin American markets for generic drug market growth could be missing a trick! The four EU countries...

RNAi Therapeutics 2008 Market Report

press@researchandmarkets.com — Thu, 13 Dec 2007 15:03:01 GMT

This is the latest RNAi-based Therapeutics Market This report presents an up-to-date thorough analysis of the RNAi therapeutics landscape based upon our continuing coverage of this dynamic marketplace This report presents an exhaustive analysis of all the therapeutics areas where research efforts...

Ethics, Law and Society - Volume 3

press@researchandmarkets.com — Tue, 27 Nov 2007 15:16:03 GMT

The third volume in a series exploring key issues in ethics, law and society, published in association with the Cardiff Centre for Ethics, Law and Society This work presents a selection of papers and commentaries on topics in bioethics, ethics and society, and business and professional ethics...

From Genes to Genomes: Concepts and Applications of DNA Technology, 2nd Edition

press@researchandmarkets.com — Fri, 26 Oct 2007 14:32:32 GMT

Rapid advances in a collection of techniques referred to as gene technology, genetic engineering, recombinant DNA technology and gene cloning have pushed molecular biology to the forefront of the biological sciences From Genes to Genomes: Concepts and Applications of DNA Technology, Second Edition...

Asymmetric Synthesis: The Essentials, Second, Completely Revised Edition

press@researchandmarkets.com — Thu, 18 Oct 2007 14:00:21 GMT

A veritable "Who's who" of asymmetric synthesis introduces the reader to the leaders in the field with a four-page concentrate of their area of research along with a short biography The book is organized into five chapters, each with an introductory preface Starting from the key concepts of...

Molecular Nutrition and Genomics: Nutrition and the Evolution of Humankind

press@researchandmarkets.com — Mon, 15 Oct 2007 11:45:57 GMT

This fascinating book draws it subject matter from a range of relevant disciplines that extend from molecular nutrition, nutritional sciences, and nutrition dietetics through to genetics, genomics, and anthropology It presents a vital portrait of the absolutely fundamental role that nutrition has...

Introduction to Soft Matter: Synthetic and Biological Self-Assembling Materials, Revised Edition

press@researchandmarkets.com — Tue, 09 Oct 2007 11:45:39 GMT

This book provides an introduction to this exciting and relatively new subject with chapters covering natural and synthetic polymers, colloids, surfactants and liquid crystals highlighting the many and varied applications of these materials Written by an expert in the field, this book will be an...

Drug Discovery Research: New Frontiers in the Post-Genomic Era

press@researchandmarkets.com — Wed, 27 Jun 2007 11:43:40 GMT

Post Genomics Drug Discovery and Research explores and discusses some of the most important topics in post-genomics life and biopharmaceutical sciences It provides an introduction to the field, outlining examples of many techniques currently used, as well as those still under development, which are...

Biomed Outsourcing Report: Biopathways, New Targets, New Opportunities in Discovery Research

press@researchandmarkets.com — Thu, 07 Jun 2007 13:53:34 GMT

A new biological paradigm, Systems Biology, has emerged with the completion of the Human Genome Project Systems biology aims to develop a systems-level understanding of biological processes System biology knowledge is complex and derives from a variety of scientific and technical disciplines...

Bioregenerative Engineering: Principles and Applications

press@researchandmarkets.com — Mon, 23 Apr 2007 13:16:17 GMT

Molecular, Cellular, and Tissue Engineering systematically addresses the foundations, principles, experimental approaches and models, and potential clinical applications of molecular, cellular, and tissue engineering The book has four units: overview, foundations, principles, and potential clinical...

Strategic Analysis of Thermal Cycler Markets in Europe

press@researchandmarkets.com — Mon, 05 Feb 2007 16:08:23 GMT

This Frost & Sullivan research service titled Strategic Analysis of Thermal Cycler Markets in Europe provides an overview of current market trends and the future of thermal cycler markets The study includes a complete analysis of key market drivers and restraints Finally, it provides strategic...

Gene Therapy-Industry Impact

press@researchandmarkets.com — Fri, 02 Feb 2007 16:56:51 GMT

This Frost & Sullivan research service titled Advances in Gene Therapy provides an overview of the current developments and advanced technologies in gene therapy, along with a complete analysis of the key market drivers, restraints, applications, and trends that are impacting this field In this...

Toxicogenomics: Primary Research Goals

press@researchandmarkets.com — Fri, 12 Jan 2007 16:40:06 GMT

This Database Table is a one-page table of hard-to-find numerical information. Database Tables are proprietary data sources covering specific information for the diagnostic, medical device, biotechnology, healthcare and IT sectors. Over 600 database tables are now available from Research and Markets.

A Note on Database Tables at Research and Markets: Please note that these database tables are very focused one or two page tables/charts. They are great as a quick snapshot of a given market, or to incorporate into your own presentations/forecasts. But they not give the detailed analysis and the comprehensive information found in the full industry/market reports. If you do require more detailed market research please visit the following categories at Research and Markets: Pharmaceuticals, Healthcare and Medical Devices, and Biotechnology.

Toxicogenomics: DNA Microarrays

press@researchandmarkets.com — Fri, 12 Jan 2007 16:40:06 GMT

Toxicogenomics: Databases Used in Toxicogenomics Research

press@researchandmarkets.com — Fri, 12 Jan 2007 16:40:05 GMT

Toxicogenomics: Data Analysis Software Usage

press@researchandmarkets.com — Fri, 12 Jan 2007 16:40:05 GMT

Microbial Genotyping: Primary Source for DNA Microarrays

press@researchandmarkets.com — Fri, 12 Jan 2007 16:39:55 GMT

Microbial Genotyping: Molecular Genotyping Techniques

press@researchandmarkets.com — Fri, 12 Jan 2007 16:39:55 GMT

Microbial Genotyping: Diagnostic and Testing Assay

press@researchandmarkets.com — Fri, 12 Jan 2007 16:39:55 GMT

Microbial Genotyping: Areas of Research

press@researchandmarkets.com — Fri, 12 Jan 2007 16:39:55 GMT

Microbial Genotyping: Applications for DNA Microarrays

press@researchandmarkets.com — Fri, 12 Jan 2007 16:39:55 GMT

Global Market for SNP Genotyping, 2000-2011

press@researchandmarkets.com — Fri, 12 Jan 2007 16:39:51 GMT

External Sources of Tissue Microarrays

press@researchandmarkets.com — Fri, 12 Jan 2007 16:39:50 GMT

Drugs in the Pipeline--An R&D Analysis

press@researchandmarkets.com — Tue, 09 Jan 2007 11:17:52 GMT

Functional Genomics Provides Easy Target Identification and Improved Drug Discovery

Functional genomics and proteomics have been quite successful in identifying the function of potential therapeutic targets, such as encoded proteins. In fact, the possible identification of 10,000 novel target antigens in the human genome signals accelerated discovery of new drugs and therapeutic molecules. As opposed to conventional sequence homology, functional genomics adds structure-based predictions to locate gene sequences with assigned and confirmed functions. It simultaneously sifts through well established targets to detect critical therapeutic targets. Such structural information results in enriched annotations that improve the identification process and also provides a clearer understanding of interactions between specific molecules and target proteins. Moreover, functional genomics is likely to bring in a higher level of efficiency to clinical research with the possibilities of genetically demarcating patients and predicting individual responses to drugs. This permits customized medications and dosages for each patient, ultimately improving treatment safety and efficacy in areas such as neuropsychiatry, cardiovascular medicine, endocrinology, and oncology.

This Frost & Sullivan research analyzes the drugs in the research and development pipelines for prominent ailments in the cardiovasular, central nervous system, and cancer therapeutic areas. Analysis of the technological trends, drivers, challenges, and recent developments assists in creating effective R&D, marketing and production strategies. The research service also discusses enabling technologies such as nanotechnology, microdosing and drug absorption studies that may be useful in accelerating early phase drug discovery efforts. Participants can identify potential collaborators, stay ahead of the competition, and stay shoulder-to-shoulder with critical developments in their respective therapeutic segments.

Inc

Strategic Analysis of World DNA Microarray Markets

press@researchandmarkets.com — Tue, 09 Jan 2007 11:17:52 GMT

Standardization of Products Necessary to Drive Acceptance of Microarrays as Diagnostic Tools

Manufacturers of DNA microarrays are seriously challenged to overcome laboratory-to-laboratory and platform-to-platform inconsistencies. Result variability can be linked to a variety of reasons including varying probe length and labeling protocols. Manufacturers are spending considerable time and effort in comparing their products with 'industry standards' that include quantitative polymerase chain reaction and other microarray platforms. Standardization of data is expected to be an essential part of microarrays becoming effective diagnostic tools.

This research examines the World DNA Microarray Markets and discusses the competitive factors in them. It segments the market into commercial, self-printed, and software products, and breaks down total revenues by the three major geographic locations - United States, Europe, and Rest-of-World. Industry challenges, strategies, market trends and opportunities are described in detail, and have been derived through extensive interviews with market participants.

Gene Expression Analyses Being Increasingly Used for Clinical Trials

Gene expression products are quickly becoming integral tools for both pre-clinical and clinical research. Gene expression analysis provides a snapshot of what is happening in a system at the molecular level, states the analyst. This information is vital to understand the workings of the system and the factors that change the system.

The utility of microarray technology in the diagnostics arena is beginning to be explored. In diagnostics, microarray technology is expected to be crucial for making decisions relating to therapeutics. Microarrays have been used in research for almost a decade; however, it is their promise as a therapeutic tool that is expected to drive the market.

Commercial Products to Drive Market Growth

World DNA microarray revenue was $596 million in 2003 and is expected to reach $93

U.S. Growth Factors Markets

press@researchandmarkets.com — Tue, 09 Jan 2007 11:17:52 GMT

Medicinal Possibilities Hold Promise of Prosperous Market

Growth factor proteins are found naturally within the body and are essential
to the growth and repair of human tissue. Recent advances in genomic

technology have enabled scientists to identify the specific genes responsible
for their creation. This has allowed for the large-scale production of growth
factors, creating a market that holds tremendous promise.

This Frost & Sullivan analysis provides a comprehensive examination of the
U.S. growth factors markets. By identifying industry drivers and evaluating
emerging challenges, this study supplies your company with a resourceful
guide to market success.

Aging Population Fuels Need for More Effective, Less Invasive Therapies

One of the greatest challenges facing the healthcare providers who treat
America’s aging population is providing access to effective therapeutics that
stimulate repair in tissues and organ systems damaged by age and disease.
Currently, there are insufficient therapies that address the underlying loss of
tissue function inherent in degenerative disorders.

Alzheimer’s disease, malignancies, trauma, autoimmune disorders, and other

similar conditions create the need for more efficient and less invasive
therapies,” says the author. “It is expected that the increase in age-related

diseases will be the most crucial driver for the growth factors industry over
the next decade.

Development of New Delivery Methods Drive Industry Evolution

Growth factors resulted from the advent of human recombinant
technologies, where biotechnology successfully mimicked the necessary
regulatory proteins for the treatment of certain ailments. Thus, new
systems are also being developed for better delivery of growth factors.
As drug discovery continues to evolve, the number of proteins that will be
discovered, sequenced, and applied to treat human diseases will increase
exponentially,” states the analyst. “Innovative de

U.S. Genetic Testing Markets

press@researchandmarkets.com — Tue, 09 Jan 2007 11:17:51 GMT

Strong Growth Forecast as Genetic Testing Gains Acceptance

Genetic testing is the highest growth segment of the diagnostics industry, with
the number of new products and services far exceeding other market sectors.

It is a frontier of tremendous potential for companies with the expertise to
develop a fully automated platform for genetic testing. With the medical
community openly voicing its approval, the healthcare industry has been

forced to re-examine the benefits of genetic screening and its billion-dollar
cost savings potential, helping to accelerate acceptance.

This Frost & Sullivan analysis offers a privileged view of the booming genetic
testing markets. By identifying emerging diagnostics trends and supplying
strategic recommendations, this research provides your firm with the detailed
information necessary to capitalize on this burgeoning field.

Micro-Chip/Array Technologies Key to Industry's Future Success

Since the mid-1990s, micro-chip/array technologies have been the promise
of the genetic testing market, allowing for disease diagnosis, drug
development, and gene research. In order to capitalize on this technology,

numerous companies have announced alliances in attempts to develop these
new diagnostic systems.

The genetic cancer testing market is ideal for micro-array/chip technologies.

Once a patient has been diagnosed with a particular gene or genetic mutation,

this technology has the potential to detect the levels at which the gene is
being expressed, states the author of this research.

Safety Benefits Outweigh Cost for Birth Defect Detection

Working in association with the Reproductive Genetics Institute, participants
are diligently developing and testing new birth defect detection methods. As a
result, several tests are already available, with more in production. Not only
do these screenings identify possible defects within embryos, but also reduce
the risk of multiple births by enabling physicians to implant fewer eggs.

Genetic

World Cancer Assay Markets

press@researchandmarkets.com — Tue, 09 Jan 2007 11:17:51 GMT

Cancer Assays Pave Way for Hybridization Technology's Success

The field of cancer assays has evolved tremendously over the years, with focus shifting from immunoassays to assessing the genetic basis of cancer. Immunoassays detect the presence of tumor markers secreted by cancer cells and operate on the premise of an antibody identifying an analyte as its antigen. Hybridization technology is now being applied to the identification of
mutations responsible for cancer development. Widespread adoption is forecast, as this technology becomes increasingly reliable as a means of cancer evaluation.
This Frost & Sullivan study provides a comprehensive analysis of the world cancer assay markets. By identifying emerging technology trends and supplying
strategic recommendations, this research allows your company to optimize revenues within this burgeoning field.

Human Genome Project Drives Industry Developments

The Human Genome Project has generated a tremendous amount of information regarding the makeup and structure of the human genome—the implications of which are incredible for the future of medicine in the areas of
diagnosis, prognosis, and treatment of cancer, states the study's author. Completion of the initial mapping of the human genome is a significant accomplishment, laying the initial groundwork for further research.
Results of the Human Genome Project only serve as background knowledge for deciphering the information obtained. Attention is now focused on the area of functional genomics, and identifying specific gene purpose and expression levels as it relates to the disease, which is expected to positively influence market growth.

Less Invasive Procedures Encourage Genetic Testing

Genetic testing serves as an alternative to traditional procedures, providing more informative results and less invasive procedures. For example, testing for cervical cancer usually involves a Pap test, which is then examined for cellular changes and often followed by a col

U.S. Pharmacogenomics Markets

press@researchandmarkets.com — Tue, 09 Jan 2007 11:17:51 GMT

Pharmacogenomics Pave the Way for Genetically Tailored Drugs

The identification of the human genome's chain sequence is revolutionizing the biotechnology and pharmaceuticals industries. Pharmacogenomics analyzes how an individual's genetic inheritance affects the body's variable response to drugs. By understanding each patient at such a profound level, pharmaceutical
manufacturers will eventually be able to produce personalized drugs that meet the unique needs of an individual's genetic makeup. Tailor-made medicines
could all but eliminate harmful drug interactions while enhancing drug efficacy, safety, and improving patients' treatments.

The field of pharmacogenomics targets specific genes for therapeutics, as well as screens genes for potential drug interactions, aiding pharmaceuticals in the
development of highly sophisticated medications. This study assesses the future of markets for genetic services (such as genetic screening), gene-based
diagnostics, and drug development for rare genetic diseases. With this in-depth research at your fingertips, your company will be poised to capitalize
on a burgeoning field.

Key Alliances and Pro-active Networking Efforts Essential for Success

Investors and established companies should begin scouting start-up companies and academic laboratories for innovative technologies, says the study's author. Forging alliances with universities' technology transfer offices, teaching hospitals, and large research institutions are crucial for market expansion.

At the same time, it is essential for participants to attend industry organization conferences to network with financial supporters of this field. Companies need to be visible and promote themselves as advocates of new
ventures, says the author. This study highlights industry challenges and offers strategic recommendations to help maximize your revenue-generating potential.

Overseas Markets Hold Promise for Orphan Drugs

Stringent healthcare regulations in foreign countri

Opportunities in the U.S. Neurogenomics Markets

press@researchandmarkets.com — Tue, 09 Jan 2007 11:17:51 GMT

Pharmaceutical companies are making huge investments in functional genomics with the expectation of reaping significant returns in the long term. This Frost & Sullivan report uses cutting-edge market valuation models to guage the expected returns on today's genomics deals in CNS. It analyzes the diseases that present the greatest revenue opportunity with an assessment of the major competitive issues and structure. With a careful examination of the challenges that face all industry players, this study can help you anticipate obstacles and develop a plan of action.

U.S., European, and Japanese Growth Hormone Markets

press@researchandmarkets.com — Tue, 09 Jan 2007 11:17:51 GMT

Driven by advances in technology and potential new indications, the growth hormone (GH) market offers significant opportunities to indsutry participants with a strategic plan of action. This Frost & Sullivan report, based on in-depth interviews with product managers, major manufacturers, distributors, and physicians, includes population-based forecasts addressing such factors as prevalence, penetration, pricing, and growth. The report addresses key issues at length, providing insightful analysis of the tactics being successfully employed by the leading market players.

Opportunities in Genomics and Associated High-Throughput Screening Markets

press@researchandmarkets.com — Tue, 09 Jan 2007 11:17:51 GMT

The genomics markets are positioned at the leading edge of the biopharmaceuticals industry and are projected to remain there through the 1990s and beyond. This Frost & Sullivan report presents an exhaustive analysis of these exciting industries, including a discussion of new product developments, quality control issues, market challenges and opportunities, and profiles of key market participants.

U.S. DNA Microarray Markets

press@researchandmarkets.com — Tue, 09 Jan 2007 11:17:50 GMT

This Frost & Sullivan research service entitled U.S. DNA Microarrays Markets thoroughly examine the Arrays Markets, Consumables Markets, Instrumentations Markets, and Software Markets.

Benefits of this Service

New Market Strategies Address Major DNA Microarrays Market Challenges
The DNA microarrays market has been faced with major challenges including, decreased NIH budgets, decreased research focus in genomics, high costs of products and receiving FDA approval. This research targets specific DNA microarrays market challenges and suggests new strategies to overcome the barriers in the market.

Thorough Research Analysis Captures Market Share Information
Frost & Sullivan research methodology is based on conducting primary interviews, which means speaking directly to top suppliers in the market. This unique research methodology, allows a complete market share analysis to be conducted with trusted information. A thorough analysis on the DNA microarrays market within the United States was completed, breaking up the top competitors in terms of percent of market held by revenue in 2005 for the arrays, software, and instrumentations market segments.

Unique Analysis Uncovers New Market Opportunities for Growth
The DNA microarrays market within the United States has been growing lucratively in the past few years in various industry sectors. The challenge for DNA microarrays manufacturers is deciding what areas to target for growth opportunities. This research deliverable identifies key opportunities for market penetration providing manufacturers with the opportunity to grow in terms of revenue.

Primary Research Identifies New Market and Technology Trends
The DNA microarrays market is evolving at an unprecendented rate in all market segments. All market segments have unique market offerings and technological advances, which are discussed in great detail throughout the research deliverable. This will provide manufacturers with the opportunity to learn about the future of D

U.S. Genetic Diagnostics Markets

press@researchandmarkets.com — Tue, 09 Jan 2007 11:17:50 GMT

Genetic Diagnostics Set to Revolutionize Healthcare Practices
The increased understanding of the genetic basis of disease and genotype/phenotype correlation has allowed genetic diagnostics to become one of the fastest growing segments in the healthcare industry. However, there are challenges surrounding reimbursement, regulation, privacy, ethical issues, and clinical validity. It has therefore become imperative to market the value proposition of genetic diagnostics in terms of marked improvements in the quality and efficiency of medical diagnosis and treatment. In the long run, as clinicians realize the benefits of early detection and elimination of redundant testing, they are likely to overlook the high costs of genetic diagnostics and eventually increase adoption.
This Frost & Sullivan research service analyzes the growing U.S. genetic diagnostics market across three main clinical applications: pharmacogenomic testing, disease screening, and predictive medicine. It discusses the various market trends and opportunities while providing an in-depth analysis of market share, revenue forecasts, and market drivers and restraints. The comprehensive focus of the study backed by strategic recommendations enables companies to align their positioning strategies to benefit from the changing market conditions and obtain maximum return on investment.

Clinicians Need for More Information with Regard to Therapeutic Treatment Drives Demand for Pharmacogenomic Testing
Pharmacogenomic testing is going to be a key driver for the uptake of genetic diagnostics as clinicians strive to acquire high quality sensitive information earlier on in the treatment process. Healthcare practitioners across the United States are working toward optimized medial treatment wherein the patient has minimal if not zero side effects, say the analyst of this research service. There is no doubt that clinicians stand to benefit from the vast amount of information available through genetic testing.
Manufactur

Developments in Pharmacogenomics (Technical Insights)

press@researchandmarkets.com — Tue, 09 Jan 2007 11:17:50 GMT

Pressure to Optimize Drug Discovery Drives Adoption Considering that the development of a single drug costs an average of $500 million and that only 30 percent of approved drugs even recover these costs, the pharmaceutical industry is under growing pressure to streamline and optimize the...

Genomics and Proteomics Markets in Australia

press@researchandmarkets.com — Tue, 09 Jan 2007 11:17:50 GMT

Increasing Research Drives Genomics and Proteomics Market in Australia

Extensive research in genomics and proteomics is promising cures for previously untreatable diseases. With the Government assisting by providing additional tax concessions, the spending on research and development (R&D) is likely to increase by 66.0 percent in 2005. As a result, more than 300 biotechnology companies focusing on genomics and proteomics applications have set up operations in Australia to take advantage of this favorable environment. Drug discovery companies are also likely to have ample opportunities to slightly modify the lead compound in order to screen and exclude patients of a certain genotype who are more prone to developing certain side effects from clinical trials.

This Frost & Sullivan research service provides an overview of and an outlook for the Australian genomics and proteomics market. It segments the market into structural and functional genomics and structural and functional proteomics. It provides detailed revenue forecasts and market share analyses and is essential for both large and small market participants seeking to position themselves to earn maximum return on investments.

Research Companies Must Team-up with Venture Capitalists for Funds

Compared to Western countries, most of the Australian biotech companies are start-up undertakings that are in need of capital to support their research. However, venture capitalists (VCs) are hesitant to provide funds since these companies have few products in the final stages of drug discovery and have to wait for around ten years for their products to complete clinical trials before releasing them into the market.

The long gestation period and the low market awareness on the potential of biotech products have led to insufficient funding of the biotech ventures in Australia as investors perceive them as being too risky, points out the analyst of the research service. The Australian government and the top research compan

Emerging Developments in Gene Therapy and DNA Vaccines

press@researchandmarkets.com — Tue, 09 Jan 2007 11:16:59 GMT

To Succeed, Gene Therapy Must Overcome Early Setbacks

Gene therapy has suffered some serious setbacks in the last few years and progress has been considerably slower than many people - particularly investors - had hoped for. The well-publicized death of one patient and the development of leukemia in three others have made it increasingly clear that careful, time-consuming research into the basic mechanisms of getting the DNA into cells, while avoiding immune attack, is essential. With more researchers joining the fray and many promising drugs in clinical trials expected to appear in the market by 2006, the potential applications for gene therapy are expanding.

This Technical Insights' study explores the various types of technologies under development for improved gene delivery. It gives an overview of several leading companies and other research institutions involved in gene therapy R&D, detailing barriers to commercialization and providing forecasts for disease sectors that are likely to benefit from this technology.

Research and Development Produces Promising Results

Once the first successful products are on the market, numerous others are sure to follow, and investor enthusiasm will most likely equal that currently enjoyed by monoclonal antibody therapies, says Dr. Katherine Austin, the analyst for this study. Some of the disorders for which gene therapies are in development - in part because they are most amenable to treatment - include hemophilia, cystic fibrosis, cardiovascular disease, and cancer. Other approaches seek to stimulate an immune response, mediate specific cell killing, activate a pro-drug, or produce a molecular decoy required for the replication of a virus.

DNA vaccines are also in clinical trials and may eventually be developed for various forms of cancer and infectious diseases such as herpes, hepatitis, and AIDS. Technology is being developed to allow vectors to target particular tissue and cell types. The obvious advantages of this i

U.S. Gene Therapy Markets

press@researchandmarkets.com — Tue, 09 Jan 2007 11:16:59 GMT

Growing Pressure for Results Renews Investor Interest in Gene Therapy
Biotech companies in the United States are facing enormous pressure to develop a gene therapy approved for marketing. While China has achieved this milestone with the world’s first approved gene therapy, Gendicine, some participants have expressed doubts whether the initial studies conformed to U.S. standards in terms of patient numbers and duration of treatment. Nevertheless, there is a great sense of urgency among these companies to have an approved gene therapy, not only to bring hope to patients suffering from unique diseases, but also to present a strong case to potential investors. Introgen Therapeutics has come closest to achieving this. With many promising late-stage pipeline products, it is helping drive the gene therapy market and boost the credibility of the technology. Other companies with vector technologies are also approaching commercial success, and their growing visibility is expected to increase the confidence of companies with gene therapy targets.
This Frost & Sullivan research service provides a comprehensive analysis of the U.S. gene therapies market, examining the present performance of pipeline products at discovery and clinical development levels and evaluating future market potential. It tracks and discusses the most critical technological breakthroughs in gene therapy research. The study also examines vectors and delivery systems in the pipeline and analyzes them by type and application.
Competitor Activity Alerts Participants on Creating Intellectual Property Portfolio
With most biotech companies still years away from having an approved and marketed gene therapy, the need to generate value within existing technologies is critical. Building an intellectual property (IP) portfolio is one of the best ways of achieving this, since it creates value and a potential revenue stream as well as protects products and technological platforms. Companies could reali

World Gene Therapy Market

press@researchandmarkets.com — Tue, 09 Jan 2007 11:16:59 GMT

Combination Trials in Gene Therapy Market to Improve Clinical Efficiency
Recent failures of clinical trials in gene therapy have caused the termination of several research projects and the retraction of many participants from the market. Only one gene therapy product, Gendicine, has reached the market in China, and its launch has been weighed down with debates about regulatory concerns over its clinical safety and efficacy. However, gene therapy still holds promise as a potential one-stop treatment for life threatening diseases. An increasingly popular method of improving clinical efficiency is to combine gene therapy trials with conventional therapeutics. These combination trials sometimes involve collaboration outside the gene therapy market with companies having established products or expertise in healthcare.
This Frost & Sullivan insight examines the current status of the world gene therapy market with a focus on its benefits and drawbacks and upcoming trends. It also provides market drivers and restraints as well as strategic analyses and recommendations to overcome industry challenges. This research enables companies to align their positioning strategies to benefit from the changing markets and obtain maximum return on investment.

High Prevalence of Untreatable Diseases Drives Demand for New Treatments
The gene therapy market has seen both devastating clinical failures and incredible breakthroughs for the treatment of severe diseases. The launch of Gendicine finally signifies a huge boost for gene therapy. The risks historically associated with gene therapy are now lessening, predominantly through scientific advances in gene delivery by industry participants.
Numerous products are in the clinical pipeline with regulatory approval anticipated within the next three years, says the analyst of this research. The market faces major challenges in patient recruitment and in the improvement of clinical success, but if these are overcome, the results will herald a

Advances in Industrial Enzymes--A Global Technology Assessment

press@researchandmarkets.com — Tue, 09 Jan 2007 11:16:37 GMT

Implementation of Assay Technologies to Help in Developing New Industrial Enzymes

The recognition and implementation of assay technologies is among the biggest challenges faced by researchers in the industrial enzymes industry. Innovative detection and high throughput technologies are expected to ease the issue and go a long way in identifying and producing newer enzymes. Advancements in biotechnology and genomics have aided the discovery of fresh enzyme sources and production strains for commercialization. The operating conditions and performance of enzyme candidates can be tuned to provide the desired performance.

This Technical Insights study, Advances in Industrial Enzymes: A Global Technology Assessment, examines the various technology drivers and restraints that control advances in industrial enzymes. The study categorizes the technology developments based on applications such as food and beverage, detergents, textiles, pulp and paper, and other industrial applications. It also discusses the various research activities at noted universities, R&D centers of leading companies, and other research institutions all over the world.

Need for Environment-friendly Technologies Drives R&D Activities

The need for cleaner and cost-effective technologies is spurring research and development activities in the field of industrial enzymes. Modern biotechnology has helped the enzyme industry develope safe host organism systems for the production of new enzymes. Leveraging the expertise of site-directed mutagenesis and cutting-edge recombinant technologies can greatly aid the development of novel enzymes for various applications, says the analyst of this research. Enzymes are not only more effective and economical than chemicals but are also safer for the environment as they reduce industrial waste.

Scientists in the pulp and paper industry have discovered that the phenol oxidase enzyme can delignify wood pulp just as efficiently as chlorine but without harming

Strategic Analysis of U.S. Genomics Markets

press@researchandmarkets.com — Thu, 04 Jan 2007 12:40:09 GMT

This research service provides a strategic analysis of genomics markets within the United States The market was divided into the total U S nucleic acid isolation markets, total U S PCR markets, total U S qRT-PCR markets, total U S DNA microarray markets, and total U S DNA sequencing technology...

U.S. DNA Sequencing Technology Markets

press@researchandmarkets.com — Mon, 18 Dec 2006 17:21:20 GMT

This research service analyzes the market for DNA sequencing technologies within the United States The market was divided into the chain terminator sequencing and next generation sequencing segments Each segment covers market trends, technology trends, competitive structure, market share analysis,...

U.S. Sequencing Services Markets

press@researchandmarkets.com — Tue, 21 Nov 2006 15:41:14 GMT

This research service analyzes the market for sequencing services within the United States. The key challenges and strategies, market and technology trends, competitive structure, market share analysis, and revenue forecasts are covered for the total market.

This Frost & Sullivan research service, entitled U.S. Sequencing Services Markets, provides revenue forecasts for the overall market with detailed market trends for specific applications, end-users, and technologies. Moreover, the research service provides in depth analysis of market-wide drivers, restraints, and challenge with the corresponding strategic recommendations. In this research, Frost & Sullivans expert analysts thoroughly examine the following markets: the total U.S. Sequencing Services Markets, and the markets for U.S. Chain Terminator Sequencing Services, Next Generation Sequencing Services, Sequencing Services for Public Sector, and Sequencing Services for Private Sector.

Market Sectors

Frost & Sullivan’s expert analysts thoroughly examine the following sectors in this research:

- Sequencing Services
- Key End-user Groups
- Sequencing Technology

Technologies

The following technologies are covered in this research:

- De novo whole genome sequencing, re-sequencing, single tube sequencing, FDA submission-quality sequencing, publication-quality sequencing, GC-rich sequencing, RNAi template sequencing, serial analysis of gene expression sequencing, viral vector sequencing, 16S ribosomal RNA gene sequencing, primer walking, SNP and mutation analysis, and methylation analysis
- Public sector end-users, which include academic institutions, hospitals, medical schools, and government agencies; and private sector end-users, which include pharmaceutical companies, biotechnology companies, and agricultural companies
- Chain terminator sequencing technologies and next generation sequencing technologies

Market Overview

The dynamics of the sequencing services market requires that participating com

Genomics and Genetics: From Molecular Details to Analysis and Techniques

press@researchandmarkets.com — Thu, 09 Nov 2006 09:52:13 GMT

With contributions by two Nobel Laureates, this careful selection of high-quality articles from the well proven Encyclopedia of Molecular Cell Biology and Molecular Medicine spans the whole range of topics in genomics and genetics The first volume deals with molecular genetics, genomic organization...

DNA Paternity Testing Centers in China and Hong Kong

press@researchandmarkets.com — Mon, 16 Oct 2006 10:08:48 GMT

This report profiles various DNA testing centers in China and Hong Kong. The profiles include a brief description about the testing centre, the products and services offered by the center and the price charged, as well as the centers contact details. The testing centres covered in the report are:

Gene Tree China,
BeiJing HuaDa FangRui Forensic Center,
The Judging Center for Forensic Material,
Jiangsu Provincial Peoples Hospital,
HeNan ShiYuan Judging Center for Forensic Material,
Jiangxi Zodogenes Co. Ltd,
Yesu Biotech Company Ltd,
DNA Diagnostics Center (DDC),
Shenzhen Tai Tai Genomics Inc,

Has Genomics Failed to Deliver?

press@researchandmarkets.com — Fri, 16 Jun 2006 11:19:48 GMT

Following its conception more than a decade ago, the field of genomics excited the research community with the possibility of a faster, surer route to drug discovery, but this optimism has quickly faded and the industry is reassessing its prospects To date, no genomics-derived product has...

Genetic Testing - Global Strategic Business Report

press@researchandmarkets.com — Tue, 06 Jun 2006 12:02:43 GMT

This report analyzes the worldwide markets for Genetic Testing in Millions of US$. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 79 companies including many key and niche players worldwide such as Abbott Laboratories, Abbott Molecular Inc., Applied Biosystems Inc., AutoGenomics, Inc., BioRad Laboratories, Celera Group, Clinical Data, Inc., Genzyme Genetics, Orchid Cellmark, Inc., PerkinElmer, Inc., Quest Diagnostics, Inc., Roche Diagnostics, Corp., Roche Molecular Diagnostics Inc., and Sciona Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.

For information on site licence pricing please click on Enquire before buying

Gene Therapy - Global Strategic Business Report

press@researchandmarkets.com — Tue, 06 Jun 2006 12:01:22 GMT

This report analyzes the world market for Gene Therapy in Millions of US$. Annual forecasts are provided for the global market for the period of 2007 through 2015. The report profiles 100 companies including many key and niche players worldwide such as AnGes MG Inc., Cell Genesys, GenVec, Genzyme Corporation, Introgen Therapeutics Inc., Oxford BioMedica, Shenzhen SiBiono GeneTech Co., Ltd., Targeted Genetics Corp., Transgene, Urigen Pharmaceuticals Inc., and Vical. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.

For information on site licence pricing please click on Enquire before buying

The Exploding RNAi Market & Future Direction Translating the Genome into a Large Market by 2009

press@researchandmarkets.com — Tue, 14 Feb 2006 14:28:52 GMT

Since its discovery in 1998 by two scientists, the naturally occurring RNA interference effect has been hailed as the hottest technical breakthrough in biological research in the last decade It may even surpass PCR as a top technology RNA interference allows scientists to silence the expression or...